



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref. No.: ADL/2-M/SE/2016

Date : 5th May, 2016

To, Department of corporate service, BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. <u>BSE CODE – 524348</u>	To, National Stock Exchange of India Limited, “Exchange Plaza”, Bandra - Kurla Complex, Bandra (E), Mumbai – 400051. <u>NSE SYMBOL: AARTIDRUGS</u>
---	---

Dear Sir/Madam,

Please find enclosed herewith copy of the press release issued by the Company on 5th May, 2016.

Please take note of the same on your record.

Thanking you,

Yours faithfully,

For **AARTI DRUGS LIMITED**

V. S. Ranade

VIBHAV S. RANADE

COMPANY SECRETARY & COMPLIANCE OFFICER

Encl: as above.





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Press release for Mar'16:

Depreciation of currencies, other macroeconomic factors in some key export markets like Latin America, other oil producing countries continue to pose challenge for global trade. In spite of these challenges, company was able to achieve growth of 8.56% for the Mar'16 quarter.

Consolidated EBITDA for the year ended Mar'16 is 175.69 crores, up by 3.55%, indicating stable operational efficiency. With growing sales and higher capacity utilization, company should be able to increase its pre-tax profitability in the coming year. Due to improved working capital cycle, company was able to reduce its Debt/Equity ratio.

Expansion project of anti-diarrheal product, which went live in Dec'15 quarter, favourably impacted domestic sales of the Mar'16 quarter. Company is actively upgrading the USFDA facility with the help of remediation plan, based on recent audit conducted by USA based consultant.

For **AARTI DRUGS LIMITED**

HARSHIT M. SAVLA
JT. MANAGING DIRECTOR

